

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Sheet	2	of	5	Application Number	10/527,931
				Filing Date	August 26, 2005
				First Named Inventor	Adrian I. Bot
				Art Unit	1633
				Examiner Name	WEHBE, ANNE MARIE SABRINA
				Attorney Docket Number	8114-008-WO-US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		TAGLIANI et al - "Selection of an Antibody Library Identifies a Pathway to Induce Immunity by Targeting CD36 on Steady-State CD8α+ Dendritic Cells." The Journal of Immunology. 2008. Vol. 180, Pgs. 3201-3209	
		BOT et al - "Immunologic Control of Tumors by In Vivo Fc(gamma) Receptor-Targeted Antigen Loading in Conjunction with Double-Stranded RNA-Mediated Immune Modulation." Journal of Immunology (Baltimore, Md.: 1950). February 2006. Vol. 176, Pgs. 1363-1374	
		PHILLIPS et al - "Recombinant immunoglobulin-based epitope delivery: A novel class of autoimmune regulators." International Reviews of Immunology. September 2005. Vol. 24 (5-6), Pgs. 501-517	
		CARVEY et al - "Intra-parenchymal injection of tumor necrosis factor-α and Interleukin 1-β produces dopamine neuron loss in the rat." Journal of Neural Transmission. May 2005. Vol. 112, Pgs. 601-612	
		JENG et al - "Roles of keratinocyte inflammation in oral cancer: regulating the prostaglandin E2, interleukin-6 and TNF-α production of oral epithelial cells by areca nut extract and arecoline." August 2003. Carcinogenesis Vol. 24, No. 8 Pgs. 1301-1315	
		COBURN et al., "siRNAs: a new wave of RNA-based therapeutics." Journal of Antimicrobial Chemotherapy." April 2003. Vol. 51, Pgs. 753-756	
		AGAMI, "RNAi and related mechanisms and their potential use for therapy." Current Opinion in Chemical Biology. December 2002. Vol. 6 (6), Pgs. 829-834	
		BONFAZ et al - "Efficient Targeting of Protein Antigen to the Dendritic Cell Receptor DEC-205 in the Steady State Leads to Antigen Presentation on Major Histocompatibility Complex Class II Products and Peripheral CD8+ T Cell Tolerance." Journal of Experimental Medicine. December 16, 2002. Vol. 196, No. 12, Pgs. 1627-1638	
		SCANLAN et al - "Cancer/testis antigens: an expanding family of targets for cancer immunotherapy." Immunological Reviews. October 2002. Vol. 188, Pgs. 22-32	
		MELÓ et al - "Gene transfer of Ig-fusion proteins into B cells prevents and treats autoimmune diseases." Journal of Immunology. May 1, 2002. Vol. 168 (9), Pgs. 4788-4795	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /AW/ (09/23/2010)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Sheet	3	of	5	Application Number	10/527,931
				Filing Date	August 26, 2005
				First Named Inventor	Adrian I. Bot
				Art Unit	1633
				Examiner Name	WEHBE, ANNE MARIE SABRINA
				Attorney Docket Number	8114-008-WO-US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		CHIRILA et al. - "The use of synthetic polymers for delivery of therapeutic antisense oligodeoxynucleotides." Biomaterials. January 2002. Vol. 23 (2), Pgs. 321-342	
		FUJITA et al. - "Overexpression of tumor necrosis factor- α produces an increase in lung volumes and pulmonary hypertension." American Journal of physiology. Lung cellular and molecular physiology. January 2001. Vol. 280, Issue 1, Pgs. L39-L49	
		ELBASHIR et al., "RNA interference is mediated by 21- and 22- nucleotide RNAs." Genes & Development. January 2001. Vol. 15 (2), Pgs. 188-200	
		SVOBODA et al., "Selective reduction of dormant maternal mRNAs in mouse oocytes by RNA interference." Development (Cambridge, England). October 2000. Vol. 127 (19), Pgs. 4147-4156	
		JEN et al., "Suppression of gene expression by targeted disruption of messenger RNA: Available options and current strategies." Stem Cells. September 2000. Vol. 18 (5), Pgs. 307-319	
		OATES et al., "Too much interference: Injection of double-stranded RNA has nonspecific effects in the zebrafish embryo." Development Biology. August 2000. Vol. 224, Pgs. 20-28	
		GREEN et al., "Antisense Oligonucleotides: An evolving technology for the modulation of gene expression in human disease." Journal of the American College of Surgeons. July 2000. Vol. 191, Pgs. 93-105	
		WIANNY et al., "Specific interference with gene function by double-stranded RNA in early mouse development." Nature Cell Biology. February 2000. Vol. 2 (2), Pgs. 70-75	
		ROMERO et al. - "Grb2 and Its Apoptotic Isoform Grb3-3 Associated with Heterogeneous Nuclear Ribonucleoprotein C, and These Interactions Are Modulated by Poly(U) RNA." The Journal of Biological Chemistry. March 27, 1998. Vol. 273, No. 13, Pgs. 7776-7781	
		BRANCH, "A good antisense molecule is hard to find." Trends in Biochemical Sciences. February 1998. Vol. 23 (2), Pgs. 45-50	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /AW/ (09/23/2010)

Substitute for form 1449/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Application Number	10/527,931	
			Filing Date	August 26, 2005	
			First Named Inventor	Adrian I. Bot	
			Art Unit	1633	
			Examiner Name	WEHBE, ANNE MARIE SABRINA	
Sheet	4	of	5	Attorney Docket Number	8114-008-WO-US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
		KHAN et al - "Polyadenylic-polyuridylic acid enhances the natural cell-mediated cytotoxicity in patients with breast cancer undergoing mastectomy." Surgery. September 1995. Vol. 118 Pgs. 531-8		
		KHAN et al - "Synthetic polyribonucleotides: current role and potential use in oncological practice." April 1995. European Journal of Surgical Oncology. Vol. 21. Pgs. 224-227		
		JOHNSON - "Molecular Adjuvants and Immunomodulators: New Approaches to Immunization." Clinical Microbiology Reviews. July 1994. Pgs. 277-289		
		BRUMEANU et al - "Efficient loading of identical viral peptide onto class II molecules by antigenized immunoglobulin and influenza virus." Journal of Experimental Medicine. November 1, 1993. Vol. 178, Pgs. 1795-1799		
		MANETTI et al - "Natural Killer Cell Stimulatory Factor (Interleukin 12 [IL-12]) Induces T Helper Type 1 (Th1)-specific Immune Responses and Inhibits the Development of IL-4-producing Th Cells." Journal of Experimental Medicine. April 1993. Volume 177, Pgs. 1199-1204		
		HENDRIX et al - "Biologic Effects after a Single Dose of Poly(I)-poly(C12U) in Healthy Volunteers. Antimicrobial Agents and Chemotherapy. March 1993. Vol. 37 (3), Pgs. 429-435		
		GOLDFELD et al - "Coordinate viral induction of tumor necrosis factor α and Interferon β in human B cells and monocytes." Proceedings of the National Academy of Sciences of the United States of America. March 1989. Vol. 86, Pgs. 1490-1494		
		WONG et al - "Tumor necrosis factors α and β inhibit virus replication and synergize with interferons." October 30, 1986. Nature Vol. 323, Pgs. 819 - 822		
		URBAN et al - "Tumor necrosis factor: A potent effector molecule for tumor cell killing by activated macrophages." Proceedings of the National Academy of Sciences of the United States of America. July 1986. Vol. 83, Pgs. 5233-5237		
		TALMADGE et al - "Immunomodulatory Effects in Mice of Polyinosinic-Polycytidylic Acid Complexed with Poly-L-lysine and Carboxymethylcellulose." Cancer Research. March 1985 Vol. 45, Pgs. 1058-1065		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /AW/ (09/23/2010)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/527,931
Filing Date	August 26, 2005
First Named Inventor	Adrian I. Bot
Art Unit	1633
Examiner Name	WEHBE, ANNE MARIE SABRINA
Attorney Docket Number	8114-008-WO-US

Sheet 5 of 5

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		YOUNG et al. - "Adjuvant Treatment with Chemotherapeutic Agents and Polyadenylic-Polyuridylic Acid in Operable Stomach Cancers." Yonsei Medical Journal. 1985. Vol. 26, No. 1, Pgs. 1-7.	
		KLEINERMAN et al. - "Constitutive Production and Release of a Lymphokine with Macrophage-activating Factor Activity Distinct from γ -Interferon by a Human T-Cell Leukemia Virus-positive Cell Line." Cancer Research. October 1984. Vol. 44, Pgs. 4470-4475	
		FLEIT et al. - "Production of Interferon by In vitro Derived Bone Marrow Macrophages." Cellular Immunology. January 15, 1981. Vol. 57, Pgs. 495-504	

Examiner Signature	/Anne Marie Wehbe/ (09/23/2010)	Date Considered	09/23/2010
--------------------	---------------------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /AW/ (09/23/2010)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INTERNAL PHP GENERATED IDS FORM

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	1	of	5
-------	---	----	---

Complete if Known

Application Number	10/527,931
Filing Date	August 26, 2005
First Named Inventor	Adrian Bot
Art Unit	1633
Examiner Name	WEHBE, ANNE MARIE SAGRINA
Attorney Docket Number	8114-008-WO-US

U. S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code3-Number 4-Kind Codes (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Comments	T6
		WO2004/027049 A2	Apr. 01, 2004	ASTRAL, INC.		
		WO2003/078595 A2	Sep. 25, 2003	ASTRAL, INC.		
		WO1998/36087	Aug. 20, 1998	AMERICAN NATIONAL RED CROSS		
		EP 1 074 617 A2	Feb. 07, 2001	HELIX RESEARCH INSTITUTE		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

XAMINER: Initial information considered "will or not at issue" in conformance with MPEP 809. Draw time taken off record if not in conference and not considered. Inadequate copies sent forth without notification to applicant. 1 Applicant's unique citation designation number (optional). 2 See KInets Codes of USPTO Patent Documents at www.uspto.gov/mpep-801.04. 3 An entrance fee issued by the document, by two-letter code (MPO Standard S) 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WPO Standard S. If 16 is possible, 6 Applicant may request a copy of the application file upon payment of \$175 per page plus \$1.97 and \$1.14 per figure. The fee schedule includes the cost of reproduction required to obtain or retain a hardcopy of the public which will be filed (and by the USPTO) to process an application. Confidentiality is governed by 35 U.S.C. 122(d)(2), 35 CFR 1.14. 7 The filing date shall include all hours complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete our initial and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1469, Alexandria, VA 22313-1469. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1460, Alexandria, VA 22313-

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /AW/ (09/23/2010)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Sheet	2	of	5	Application Number	10/527,931
				Filing Date	August 26, 2005
				First Named Inventor	Adrian I. Bot
				Art Unit	1633
				Examiner Name	WEHBE, ANNE MARIE SABKINA
				Attorney Docket Number	8114-008-WO-US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		TAGLIANI et al. - "Selection of an Antibody Library Identifies a Pathway to Induce Immunity by Targeting CD36 on Steady-State CD8 α ⁺ Dendritic Cells." The Journal of Immunology. 2008. Vol. 180, Pgs. 3201-3209	
		BOT et al. - "Immunologic Control of Tumors by In Vivo Fc(gamma) Receptor-Targeted Antigen Loading in Conjunction with Double-Stranded RNA-Mediated Immune Modulation." Journal of Immunology (Baltimore, Md.: 1950). February 2006. Vol. 176, Pgs. 1363-1374	
DUPLICATE		PHILLIPS et al. - "Recombinant Immunoglobulin-based epitope delivery: A novel class of autoimmune regulators." International Reviews of Immunology. September 2005. Vol. 24 (5-6), Pgs. 501-517	
		CARVEY et al. - "Intra-parenchymal injection of tumor necrosis factor- α and Interleukin 1- β produces dopamine neuron loss in the rat." Journal of Neural Transmission. May 2005. Vol. 112, Pgs. 601-612	
		JENG et al. - "Roles of keratinocyte inflammation in oral cancer: regulating the prostaglandin E2, Interleukin-6 and TNF- α production of oral epithelial cells by areas not extract and arecoline." August 2003. Carcinogenesis Vol. 24, No. 8 Pgs. 1301-1315	
		COBURN et al. - "siRNAs: a new wave of RNA-based therapeutics." Journal of Antimicrobial Chemotherapy. April 2003. Vol. 51, Pgs. 753-756	
		AGAMI, "RNAi and related mechanisms and their potential use for therapy." Current Opinion in Chemical Biology. December 2002. Vol. 6 (6), Pgs. 829-834	
		BONIFAZ et al. - "Efficient Targeting of Protein Antigen to the Dendritic Cell Receptor DEC-205 in the Steady State Leads to Antigen Presentation on Major Histocompatibility Complex Class I Products and Peripheral CD8 ⁺ T Cell Tolerance." Journal of Experimental Medicine. December 16, 2002. Vol. 196, No. 12, Pgs. 1627-1638	
		SCANLAN et al. - "Cancer/testis antigens: an expanding family of targets for cancer immunotherapy." Immunological Reviews. October 2002. Vol. 188, Pgs. 22-32	
		MELO et al. - "Gene transfer of Ig-fusion proteins into B cells prevents and treats autoimmune diseases." Journal of Immunology. May 1, 2002. Vol. 168 (9), Pgs. 4788-4795	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/527,931
Filing Date	August 26, 2005
First Named Inventor	Adrian I. Bot
Art Unit	1633
Examiner Name	WEHBE, ANNE MARIE SABKINA
Attorney Docket Number	8114-008-WO-US

Sheet **3** of **5****NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		CHIRILA et al. - "The use of synthetic polymers for delivery of therapeutic antisense oligodeoxynucleotides." Biomaterials. January 2002. Vol. 23 (2), Pgs. 321-342	
		FUJITA et al. - "Overexpression of tumor necrosis factor- α produces an increase in lung volumes and pulmonary hypertension." American Journal of physiology. Lung cellular and molecular physiology. January 2001. Vol. 280, Issue 1, Pgs. L39-L49	
DUPLICATE		ELBASHIR et al., "RNA interference is mediated by 21- and 22- nucleotide RNAs." Genes & Development. January 2001. Vol. 15 (2), Pgs. 188-200	
		SVOBODA et al., "Selective reduction of dormant maternal mRNAs in mouse oocytes by RNA interference." Development (Cambridge, England). October 2000. Vol. 127 (19), Pgs. 4147-4156	
		JEN et al., "Suppression of gene expression by targeted disruption of messenger RNA: Available options and current strategies." Stem Cells. September 2000. Vol. 18 (5), Pgs. 307-319	
		OATES et al., "Too much interference: Injection of double-stranded RNA has nonspecific effects in the zebrafish embryo." Development Biology. August 2000. Vol. 224, Pgs. 20-28	
		GREEN et al., "Antisense Oligonucleotides: An evolving technology for the modulation of gene expression in human disease." Journal of the American College of Surgeons. July 2000. Vol. 191, Pgs. 93-105	
		WIANNY et al., "Specific interference with gene function by double-stranded RNA in early mouse development." Nature Cell Biology. February 2000. Vol. 2 (2), Pgs. 70-75	
		ROMERO et al. - Grb2 and Its Apoptotic Isoform Grb3-3 Associated with Heterogeneous Nuclear Ribonucleoprotein C, and These Interactions Are Modulated by Poly(U) RNA." The Journal of Biological Chemistry. March 27, 1998. Vol. 273, No. 13, Pgs. 7776-7781	
		BRANCH, "A good antisense molecule is hard to find." Trends in Biochemical Sciences. February 1998. Vol. 23 (2), Pgs. 46-50	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance, and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Sheet	4	of	5
Application Number		10/527,931	
Filing Date		August 26, 2005	
First Named Inventor		Adrian I. Bot	
Art Unit		1633	
Examiner Name		WEHBE, ANNE MARIE SABKINA	
Attorney Docket Number		8114-008-WO-US	

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		KHAN et al - "Polyadenylic-polyuridylic acid enhances the natural cell-mediated cytotoxicity in patients with breast cancer undergoing mastectomy." Surgery. September 1995. Vol. 118 Pgs. 531-8	
		KHAN et al - "Synthetic polyribonucleotides: current role and potential use in oncological practice." April 1995. European Journal of Surgical Oncology. Vol. 21, Pgs. 224-227	
		JOHNSON - "Molecular Adjuvants and Immunomodulators: New Approaches to Immunization." Clinical Microbiology Reviews. July 1994. Pgs. 278-289	
DUPLICATE		BRUMEANU et al - "Efficient loading of identical viral peptide onto class II molecules by antigenized immunoglobulin and Influenza virus." Journal of Experimental Medicine. November 1, 1993. Vol. 178, Pgs. 1795-1799	
		MANETTI et al - "Natural Killer Cell Stimulatory Factor (Interleukin 12 [IL-12]) Induces T Helper Type 1 (Th1)-specific Immune Responses and Inhibits the Development of IL-4-producing Th Cells." Journal of Experimental Medicine. April 1993. Volume 177, Pgs. 1195-1204	
		HENDRIX et al - Biologic Effects after a Single Dose of Poly(I):poly(C)[I2U] in Healthy Volunteers. Antimicrobial Agents and Chemotherapy. March 1993. Vol. 37 (3), Pgs. 429-435	
		GOLDFELD et al - "Coordinate viral induction of tumor necrosis factor α and interferon β in human B cells and monocytes." Proceedings of the National Academy of Sciences of the United States of America. March 1989. Vol. 86, Pgs. 1490-1494	
		WONG et al - "Tumor necrosis factors α and β inhibit virus replication and synergize with interferons." October 30, 1986. Nature Vol. 323, Pgs. 819 - 822	
		URBAN et al - "Tumor necrosis factor: A potent effector molecule for tumor cell killing by activated macrophages." Proceedings of the National Academy of Sciences of the United States of America. July 1988. Vol. 83, Pgs. 5233-5237	
		TALMAGE et al - "Immunomodulatory Effects in Mice of Polyinosinic-Polycytidylic Acid Complexed with Poly-Vinyl and Carboxymethylcellulose." Cancer Research. March 1985 Vol. 45, Pgs. 1058-1065	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance, and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	10/527.931
--------------------	------------

Filing Date	August 26, 2005
--------------------	------------------------

First Named Inventor	Adrian I. Bot
----------------------	---------------

Art Unit	1633
----------	------

Examiner Name	WEHBE, ANNE MARIE SABRINA
---------------	---------------------------

Attorney Docket Number	8114-008-W0-IIS
------------------------	-----------------

Sheet	5	of	5
-------	---	----	---

NON PATENT LITERATURE DOCUMENTS

[illegible]

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached

This collection of information is required by 37 CFR 1.58. The information is required to obtain or retain a benefit that the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.